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Abstract 
BACKGROUND: Colorectal Adenocarcinoma (ADCCR) is the third most cancer not only in the world but also in 
Indonesia. There were 623 cases of ADCCR at Dr Hasan Sadikin hospital within 2015-2017. Both KRAS and 
TP53 mutation are known as genes which involve in carcinogenesis through the same pathway, namely the 
chromosomal instability pathway. In West Java, researches focusing on mutation KRAS and p53 also a 
correlation between both biomarkers among ADCCR patients are still limited.  
AIM: Therefore, this research aimed to perceive a correlation between KRAS gene expression with p53 
immunoexpression in ADCCR. 
METHODS: Cross section research design was performed to 62 cases of ADCCR as paraffin block taken from 4 
hospitals in West Java, including Dr Hasan Sadikin hospital Bandung, Santosa hospital Bandung, Borromeus 
hospital Bandung and Syamsudin hospital Sukabumi from January 1st 2014 to 31s November 2018. KRAS 
mutation gene data taken from secondary data at molecular laboratory in Ciptomangunkusumo Hospital Jakarta 
and Dr Sardjito Hospital Jogjakarta, while the detection of p53 immunoexpression data using 
immunohistochemical staining was carried out in the Laboratorium of Anatomical Pathology of Padjadjaran 
University (Dr Hasan Sadikin Hospital). All data were analysed using Chi-Square test with p-value < 0,05 of 
significant level then proceeded with Stata ver.11 for windows. 
RESULTS: The results of this study showed that KRAS gene expressions from 62 sample consist of 39 wild type 
KRAS (62.39%) and 23 mutant KRAS (37.1%). The p53 immunoexpression consists of 27 negative cases (non-
mutant p53) and 35 mutant p53, which includes 10 cases as focal expression (16.33%) and 25 cases as diffuse 
expressions (40.33%). There is a significant association between KRAS gene expression and p53 
immunoexpressions in ADCCR (p = 0.04), with mild positive correlation (Rho 0.28).  
CONCLUSION: This study concluded that KRAS and p53 mutations are involved in carcinogenesis, and the p53 
mutation is a more dominant risk factor than KRAS mutation among West Java people. P53 mutations with diffuse 
pattern tend to express mutant KRAS while p53 negative and having a focal pattern tend to express wt KRAS. 
 
 
 
Introduction 
 
Colorectal carcinoma (CRC) is a malignant 
epithelial tumour originating in the large bowel. 
Colorectal carcinoma ranks as the third most frequent 
cancer not only in the world but also in Indonesia [1], 
[2].
 
The worldwide mortality rate is about 608.000 
deaths [2]. In Indonesia, the mortality rate is about 
9.5% of all cancer deaths [3], [4].
 
According to data 
from the Department of Anatomy Pathology Dr Hasan 
Sadikin Hospital Bandung, the frequency of CRC is 
about 224 cases in 2015, 187 cases in 2016 and 212 
cases in 2017.  
Colorectal Adenocarcinoma (ADCCR) is the 
most frequent type 0f CRC in the world [1]. There are 
many mutation genes occur in ADCCR, such as 
Adenomatous Polyposis Coli (APC), TP53, Kirsten rat 
sarcoma virus (KRAS), PIK3CA, etc. [5]. These genes 
are involved in carcinogenesis through three major 
pathways such as chromosomal instability, mismatch 
repair and CpG island methylator phenotype (CIMP). 
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The most frequent pathway is chromosomal instability, 
about 65% [6], [7].
 
Three genes are involved in this 
pathway; they are: 1) APC gene mutation as an 
initiator in the early phase of carcinogenesis. 2) 
Kirsten rat sarcoma virus gene mutation, which occurs 
in 50% of ADCCR from intermediate phase to 
advance phase. 3) TP53 gene mutation in the late 
phase of carcinogenesis is about 40-60% (Figure 1) 
[6].  
 
Figure 1: KRAS mutation can occur together with p53 mutation in 
the late phase of carcinogenesis. Both of them involved in the same 
pathway of carcinogenesis (instability chromosome pathway) 
 
KRAS gene expression consists of wild type 
(wt) KRAS and mutant KRAS. Wild type KRAS gene 
is located in short arm of chromosome number 12, in 
12 p12.1. This product is wt KRAS protein, which can 
flip back and forth between an excited signal 
transmitting state and quiescent state. RAS is inactive 
when bound to GDP, but stimulation of cells by growth 
factors such as EGF and PDGF leads to an exchange 
of GDP for GTP and subsequent conformational 
changes that generate active RAS and stimulate 
downstream regulators of cells proliferation [6], [8].
 
This excited signal emitting state, in short, 
lived
, 
however, because the intrinsic guanosine 
triphosphatase (GTPase) activity of wt RAS 
hydrolyses GTP to GDP return the active wt KRAS to 
its inactive state [8].
 
In ADCCR wt KRAS will always 
be active because EGF stimulates continuously. 
ADCCR patients with wt KRAS have a good response 
to anti-epidermal Growth Factor Receptor (EGFR) 
drugs such as cetuximab and panitumumab [1], [9], 
[10], [11].
 
In contrast, mutant KRAS was not 
responsive to anti-EGFR inhibition [1], [3], [12].
 
Mutant 
KRAS
 
can be active continuously although having 
limited EGFR stimulation. This gene has GTP-ase 
activity lower than wt KRAS, resulting in a decrease of 
hydrolysing activity 3-9 times lower than wt KRAS. 
This situation makes the irreversible signal to 
downstream regulation
 
to provide uncontrolled 
proliferation and differentiation cells [8].
 
 
Mutant KRAS gene occurs in exon 2, 3 and 4. 
Exon 2 is the frequent site of mutation [12] — mutant 
KRAS gene as a predictive negative response from 
anti-EGFR therapy. Patient with mutant KRAS has a 
worse prognosis than those with wt KRAS. Product of 
mutant KRAS gene is mutant KRAS protein [1], [9], 
[10], [12].
  
In ADCCR another abnormality is Tumor 
Protein (TP) 53 pathway consists of loss of function wt 
TP53 and the increase of TP53 mutant concentration. 
Wild type TP53 is normally in the latent phase and will 
be stabilised and activated by genotoxic agent and 
another stress signal. Regulatory of TP53 is Murine 
Double minute 2 (Mdm2), a protein which can bind 
TP53 in unstable or inactivated conditions. TP53 gene 
can be activated by the detachment of TP53 from 
Mdm2. This condition makes this gen stop the cell 
cycle and repairing DNA breakdown and involving in 
apoptosis and ageing [6]. 
In the state of activated p53 due to release 
from Mdm2, p53 will have the ability to trigger cell 
cycle discontinuation, repair DNA damage and be 
involved in the process of apoptosis and cell ageing 
[6]. One of the p53 gene mutations is caused by the 
loss of alleles on the chromosome on the short arm of 
chromosome 17, resulting in genomic disorders that 
occur in the later phase of tumour progression [8].
 
Most TP53 mutations occur in exons 5 to 8, which 
encode residues 130-286, which are important and 
responsible for folding and stabilising tertiary 
structures of proteins [8].
 
Mutations in the P53 gene 
can result in loss of wild type TP53 ability for DNA 
repair, apoptosis, checkpoints, and cell ageing 
processes [8], [9], [10]. Also, the TP53 mutation 
produces a mutant P53 gene which acts as an 
oncogene, thereby increasing the aggressiveness, 
survival and metastasis ability of the tumour cell [13], 
[14].
 
The product of the P53 gene mutation is a mutant 
p53 protein that can be examined by several methods, 
including the Immunohistochemical (CPI) method [8], 
[9], [10].
 
The expression of the KRAS and TP53 genes 
are mostly associated with pathological features, 
lymph node metastasis, distant metastasis and 
ADCCR therapy response [10, [15], [16], [17].
 
The role 
of these two molecular markers is widely used as a 
predictor of prognosis of ADCCR therapy. The 
Assesment of the anti p53 antibody with 
immunohistochemistry methods is lower in cost but 
more effective and efficient. Thus it can be considered 
as one alternative to predict KRAS gen expressions in 
ADCCR patients. However, studies involving the 
relationship of KRAS mutations as one of the stress 
signals in tumour cells with mutant Immunoexpression 
p53 are still not widely performed and documented [6], 
[10], [13], [14], [15], [16], [17]. 
 The objective of this study is to understand 
the relationship and correlation between KRAS gene 
expression and p53 immunoexpression in ADCCR. 
 
 
Methods 
 
Samples were obtained from tissue biopsy 
and or colectomy of surgery patients registered at Dr 
Hasan Sadikin Hospital Bandung, Santosa hospital 
Bandung, Borromeus hospital Bandung and 
Syamsudin hospital Sukabumi. Histopathologically 
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diagnosed with ADCCR from January 1
st
, 2014 until 
November 31
st
, 2018. Samples were attained after 
approved by the Ethical Committee with assessment 
number 105/UN6.KEP/EC/2019, and then drawn 
according to inclusion criteria. 
Sixty-two samples of KRAS gene expression 
had been checked in the molecular laboratory, 
Ciptomangunkusumo Hospital Jakarta and Sardjito 
Hospital Jogjakarta. To see if mutation in exon 2 
occur, the KRAS mutation using PCR-HRM (High-
Resolution Melting-Polymerase Chain Reaction) 
methods was combined with RFLP (Restriction 
fragment length polymorphism) and to see if mutation 
in exon 3 and 4 occur, the KRAS mutation using PCR-
HRM (High-Resolution Melting-Polymerase Chain 
Reaction) methods was combined with direct DNA 
sequencing. KRAS mutation is positive if there is ‘split 
peaks’ in the melting curve that shows two 
populations (wild type and mutant allele) and occurs in 
at least 1 out of 3 exons. KRAS mutation is negative 
(wild type) if there are no ‘split peaks. These gene 
expressions data were recorded and collected as 
secondary data in this research 
P53 immunoexpression had been checked by 
immunohistochemistry staining procedure at the 
Laboratorium of Anatomical Pathology of Padjadjaran 
University (Dr. Hasan Sadikin Hospital. 
Immunohistochemistry staining using mouse 
monoclonal antibody p53 (Santa Cruz, Pab-1801, SC-
98) with dilution 1:150 was used in standard 
immunohistochemistry (IHC) staining procedure. 
Immunoexpression of p53 was categorised by 
calculating the distribution of the cells that showed 
immunoreactivity, which was the nucleus-stained 
cells. Distribution score was explained as 0 = 
negative; Focal = 1-50%; Diffuse = ≥ 50%. Intensity 
compares with breast cancer cells as an internal 
positive control. IHC staining result was examined by 
two experts in the IHC technique using light 
microscope Olympus CX31. 
  
Statistical analysis 
The data obtained from this research was 
analysed using Chi-Square test and Spearman Rho 
correlation. A significant association was interpreted 
from p-value where p ≤ 0.05 showed a statistically 
significant association, while p ≥ 0.05 showed 
otherwise. If the Spearman rho was not equal to 0, the 
significant correlation showed. If Spearman rho = 0, it 
showed otherwise. The data attained from laboratory 
procedure was recorded in a distinct form, and Stata 
ver 11 for Windows was used to be analysed 
statistically. 
 
 
 
Results 
 
The characteristics of the research subjects 
are based on age, gender and the degree of ADCCR 
differentiation as mention in table 1. Age < 40 years 
as many as 8 cases (12.90%), age 40-60 years as 
many as 35 cases (56.45%) and age > 60 years as 
many as 19 cases (30.65%). The youngest is 26 
years old, and the oldest is 81 years old, and the 
middle value is 54 years. The males are 33 people 
(53.23%), and females are 29 people (46.77%). 
Histological degree in ADCCR consists of 42 well-
differentiated cases (67.74%), 10 cases for each 
moderately and poorly differentiated (16.13%). 
Table 1. Research patient's characteristic  
Characteristics ADCCR (n = 62) 
Age (years)  
Mean ± Std 54 ± 12 
Median (min, maks) 54 (26.81) 
     years 8 (12.9%) 
40-60 years 35 (56.45%) 
     years 19 (30.65%) 
Sex   
Male 33 (53.23%) 
Female 29 (46.77%) 
Histological degree  
Well 42(67.74%) 
Moderately 10 (16.13%) 
Poorly 10 (16.13%) 
 
 Based on secondary data from PCR 
examination, KRAS gene expression includes wt 
KRAS (negative mutation) and KRAS mutants. P53 
immunoexpression in this study was assessed from 
the brown stained of the tumour cell nucleus. The 
result of p53 immunohistochemical staining was 
assessed based on tumour cell distribution consisting 
of negative, focal and diffuse. The results of the data 
and calculations are shown in Table 2. 
 Table 2 shows the descriptive data 
distribution regarding the frequency of the KRAS gene 
expression and p53 immunoexpression. It is shown 
that the most visible KRAS gene expression is wt 
KRAS as many as 39 cases (62.39%), KRAS 
mutations occur in only 23 cases (37.1%). The highest 
p53 Immunoexpression is in the negative distribution 
of 27 cases (43.55%), diffuse distribution of 25 cases 
(40.32%), and the focal distribution of 10 cases 
(16.13%). 
Table 2: KRAS Gene Expression and p53 
Immunoexpression 
Characteristics ADCCR (n = 62) 
KRAS gene expression  
Wt KRAS (negative mutation) 39 (62.39%) 
Mutant KRAS  23 (37.1%) 
P53 immunoexpression  
Negative 27 (43.55%) 
Focal 10 (16.13%) 
Diffuse 25 (40.33%) 
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 In this study, the statistical tests were using 
Chi-square to analyse the relationship between 
expression of the KRAS gene and immunoexpression 
of TP53 in ADCCR and using Spearman Rho to 
analyse the correlation between expression of the 
KRAS gene and immunoexpression of TP53 in 
ADCCR. The result is a significant relationship with a 
value of p = 0.04 (p < 0.05)), with positive mild 
correlation (Rho 0.28) as shown in Table 3. 
Table 3: Correlation of KRAS Gene Expression with p53 
Immunoexpression  
 
KRAS 
P53 Immunoexpression  
P value 
(Chi 
Square) 
Spearman 
Rho 
(Correlation) 
P(Spearman) 
Negative Focal Diffuse 
Wt 20 (74.07%) 8 (80%) 11 (44%)  
0.04 
 
0.28 
 
0.03 Mutant 7 (25.93%) 2 (20%) 14 (56%) 
 
 Immunoexpression of p53 was categorised 
by calculating the distribution of the cells that showed 
immunoreactivity, which was the nucleus-stained 
cells. Distribution score was explained as 0 = 
negative; Focal = 1-50%; Diffuse = ≥ 50%. The figure 
below showed the distribution of p53 in tumour cells 
more than 50% categorised as Diffuse distribution. 
 
Figure 2: A) Immunoexpression p53 diffuse distribution 
(magnification 40 x ); B) Immunoexpression p53 diffuse distribution 
(magnification 100 x) 
 
 
Discussion  
 
The collection of KRAS gene expression 
examination data in all ADCCR cases was carried out. 
The result is that the KRAS mutation only occurs in 23 
cases (37.1%). This figure is lower than the data 
obtained from the literature (50%), but it is higher than 
the research conducted by Sameer et al. in Kashmir 
ethnicity which was 22.6% [4], [6].
 
The results of the 
KRAS secondary data collection showed that 62.9% 
of ADCCR in this study has a wild type gene 
expression profile. In ADCCR through the wt KRAS 
pathway, continuous KRAS activation will occur 
because it is stimulated continuously by growth 
factors, one of which is EGF which will bind to EGFR 
to subsequently induce various proteins that help 
KRAS phosphorylation process. Phosphorylated 
KRAS is KRAS, which is bound to GTP, which will 
give hyperproliferative signals to cancer cells [1], [6], 
[18]. 
ADCCR patients with wt KRAS status have a 
good response to anti-EGFR therapy [8], [18].
 
This 
study shows that 62.9% of ADCCR cases in this study 
had a good response to anti-EGFR, such as 
cetuximab and panitumumab [1], [3], [11], [18].
 
 
Patients with wt KRAS will have a better 
prognosis than patients with mutant KRAS [1], [8], 
[18]. The ability of tumour cells to proliferate, 
differentiate, invade, and metastasis is not as bad as 
in ADCCR patients with mutant KRAS status. This is 
by the most differentiation degrees in this study, 
namely low degrees with better prognosis (67.74%). 
KRAS mutations only occurred in 23 cases (37.1%). 
These results indicate that it is necessary to consider 
other alternative carcinogenesis pathways in ADCCR 
in West Java in addition to the CIN pathway. 
In ADCCR, the TP53 pathway can experience 
abnormalities, including loss of function wt TP53 and 
increased mutant TP53 levels [10].
 
The products of 
the two genes are wt p53 and p53 mutant proteins. In 
this study, the measured protein is the p53 mutant 
using the IHK method, and the results of the 
assessment are thus referred to as p53 
immunoexpression. The results of this study showed 
that the highest p53 immunoexpression was 27 cases 
of negative distribution (43.55%), 25 cases of diffuse 
distribution (40.32%) and 10 cases of focal distribution 
(16.13%). These results showed mutant p53 occurred 
in 35 cases (56, 45%). These results are in line with 
the literature, which states that p53 mutations can 
occur in as many as 40-60% of ADCCR cases [10].
 
It 
was higher than the incidence of ADCCR which was 
identified as having a TP53 gene mutation in Saudi 
Arabia of 33.7% but data from WHO showed a higher 
mutation of 80% [1], [16].
 
In this study, the statistical tests were using 
Chi-square to analyse the relationship between 
expression of the KRAS gene and immunoexpression 
of TP53 in ADCCR and using Spearman Rho to 
analyse the correlation between expression of the 
KRAS gene and immunoexpression of TP53 in 
ADCCR. The result is a significant relationship with a 
value of p = 0.04 (p < 0.05)), with positive mild 
correlation (Rho 0.28). This may be due to the 
activation of the wt KRAS by excessive growth factors 
signal that will cause cell stress due to 
hyperproliferative signals caused by stimulation of 
proteins involved in the KRAS pathway which 
activates the cell nucleus for the process of 
transcription and proliferation [13], [14].
 
This causes 
various activation of E2F protein, a protein involved in 
triggering the role of tumour suppressor genes such 
as TP53, RB, and P21 [13], [14]. 
 
The signalling pathway that connects the 
KRAS mutation with wildtype TP53 has been widely 
documented, one of which is research on mice that 
have become experimental animal models for lung 
cancer. The results of the study stated that the KRAS 
mutations that occur could lead to excessive cell 
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proliferation. This Hyperproliferative signal is 
considered a stress signal which triggers the release 
of wt TP53 from Murine Double Minute 2 (Mdm2). 
This results in wt TP53 being able to stop the cell 
cycle and trigger the apoptosis program and protect 
cells from abnormal growth factors [13].
 
One study reported that the correlation of 
KRAS mutations in ADCCR patients had a low 
prevalence of TP53 mutations. This result contrary to 
this study, which wt KRAS tend to show high frequent 
of negative (20/27; 74.07%) and focal (8/10; 80%) 
TP53 mutant. This is possible because the mutations 
occurred in ADCCR in the study were indeed low so 
that the wt KRAS predominant as hyperproliferative 
stress compare than mutant KRAS and will trigger the 
wt TP53 pathway, especially for well-differentiated 
and less aggressive tumours, characterised by slow 
growth and low metastatic ability. This was caused by 
the fact that TP53 still functions as a tumour 
suppressor and have a little oncogenic ability [13], 
[14], [20]. In this study, the proportion of KRAS 
mutations was low in the wt KRAS, whereas positive 
p53 immunoexpression (mutant p53) was higher than 
the negative (non-mutant p53). This is possible 
because the KRAS mutation in ADCCR in this study 
had little role in carcinogenesis in the CIN pathway 
compared to TP53 mutations. This result shows that 
ADCCR among west java people mostly occurred 
sporadically. 
In conclusion, a mild correlation occurs in the 
relationship between the expression of the KRAS 
gene and p53 immunoexpression in ADCCR In the 
case of ADCCR with diffuse p53 immunoexpression, it 
expresses or predicts the expression of mutant KRAS 
genes. On the contrary, in the case of ADCCR with 
negative and focal p53 immunoexpression, it tends to 
express or predict the expression of the wt KRAS 
gene. 
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